-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Read: Ed Bio's "Multigene Joint Detection Product for Lung Cancer" will be used in the Merck MET inhibitor Tepotinib's accompanying diagnostic registration in Japan.
recently, Xiamen Eide Biopharmaceutical Technology Co., Ltd. and MERCK KGaA signed a cooperation agreement.
Ed Bio's self-developed "Lung Cancer Multigene Joint Detection Product" (i.e. Ai Huijian ® Upgrade) developed on the PCR technology platform will be used for the Merck MET inhibitor Tepotinib's accompanying diagnostic registration in Japan. Tepotinib, a
Merck MET inhibitor, was approved by Japan's Ministry of Health, Labour and Welfare in March 2020 for the treatment of non-small cell lung cancer patients with MET exon 14 jump mutation.
Ed Bio's independent research and development of "Ai Huijian ®" (can detect multiple lung cancer core driving genes) has been approved by the State Drug Administration on August 24, 2018, this cooperation, Ai Huijian ® upgraded version has once again become Merck lung cancer target drug clinical accompanying diagnostic products, highlighting Ed Bio at home and abroad in the field of cancer diagnosis advantage swell and brand influence.
.
